Standard Chemical & Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Standard Chemical & Pharmaceutical yıllık ortalama 17.5% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 8.8% annual. Gelirler growing yılda ortalama 12% oranında artmaktadır. Standard Chemical & Pharmaceutical'in özkaynak karlılığı 13.9% ve net marjı 12.9%'dir.

Anahtar bilgiler

17.5%

Kazanç büyüme oranı

17.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	18.5%
Gelir büyüme oranı	12.0%
Özkaynak getirisi	13.9%
Net Marj	12.9%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70

Jul 29

Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70

Jul 14

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

Apr 13

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 19

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Jan 04

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

Dec 22

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Dec 08

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Nov 26

Gelir ve Gider Dağılımı

Standard Chemical & Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TWSE:1720 Gelir, gider ve kazançlar (TWD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	6,611	854	1,272	286
31 Mar 24	6,360	877	1,225	270
31 Dec 23	6,240	835	1,200	266
30 Sep 23	6,231	848	1,148	252
30 Jun 23	6,135	863	1,174	246
31 Mar 23	6,107	853	1,151	250
31 Dec 22	5,851	815	1,117	252
30 Sep 22	5,501	813	499	256
30 Jun 22	5,072	734	988	249
31 Mar 22	4,740	672	970	243
31 Dec 21	4,604	707	949	242
30 Sep 21	4,489	694	980	237
30 Jun 21	4,413	649	983	239
31 Mar 21	4,372	612	973	233
31 Dec 20	4,305	524	986	227
30 Sep 20	4,219	461	962	220
30 Jun 20	4,223	455	975	224
31 Mar 20	4,125	425	979	225
31 Dec 19	3,937	376	968	226
30 Sep 19	3,905	374	981	229
30 Jun 19	3,769	383	966	217
31 Mar 19	3,656	383	955	216
31 Dec 18	3,573	374	933	225
30 Sep 18	3,480	329	927	228
30 Jun 18	3,624	366	951	236
31 Mar 18	3,702	367	942	248
31 Dec 17	3,849	363	968	240
30 Sep 17	3,898	393	942	252
30 Jun 17	3,761	347	918	248
31 Mar 17	3,725	319	935	243
31 Dec 16	3,674	340	917	241
30 Sep 16	3,635	338	931	250
30 Jun 16	3,529	323	918	247
31 Mar 16	3,374	325	876	238
31 Dec 15	3,321	348	873	239
30 Sep 15	3,280	345	890	221
30 Jun 15	3,275	349	866	233
31 Mar 15	3,304	381	853	239
31 Dec 14	3,296	374	828	243
30 Sep 14	3,203	334	803	253
30 Jun 14	3,125	292	797	243
31 Mar 14	3,069	277	823	235
31 Dec 13	3,054	299	806	226

Kaliteli Kazançlar: 1720 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 1720 'nin mevcut net kar marjları (12.9%) geçen yılın (14.1%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1720 şirketinin kazancı son 5 yılda yılda 17.5% oranında arttı.

Büyüme Hızlandırma: 1720 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 1720 geçtiğimiz yıl negatif kazanç büyümesine ( -1% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( -0.6% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 1720 'nin Özsermaye Getirisi ( 13.9% ) düşük olarak değerlendiriliyor.

Standard Chemical & Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings released: EPS: NT$1.21 (vs NT$1.33 in 2Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: NT$1.41 (vs NT$1.18 in 1Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: EPS: NT$4.67 (vs NT$4.56 in FY 2022)

Third quarter 2023 earnings released: EPS: NT$1.25 (vs NT$1.34 in 3Q 2022)

Recent updates

Second quarter 2024 earnings released: EPS: NT$1.21 (vs NT$1.33 in 2Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70

Upcoming dividend of NT$2.70 per share

Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70

Dividend of NT$2.70 announced

High number of new directors

First quarter 2024 earnings released: EPS: NT$1.41 (vs NT$1.18 in 1Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: EPS: NT$4.67 (vs NT$4.56 in FY 2022)

Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2023 earnings released: EPS: NT$1.25 (vs NT$1.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$1.33 (vs NT$1.28 in 2Q 2022)

Upcoming dividend of NT$2.50 per share at 3.8% yield

Standard Chemical & Pharmaceutical Co. Ltd. Elects One Additional Director and One Additional Independent Director

Investor sentiment improves as stock rises 22%

Full year 2022 earnings released: EPS: NT$4.56 (vs NT$3.96 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$1.34 (vs NT$0.89 in 3Q 2021)

Now 20% undervalued

Now 20% undervalued

Second quarter 2022 earnings released: EPS: NT$1.28 (vs NT$0.93 in 2Q 2021)

Upcoming dividend of NT$2.50 per share

First quarter 2022 earnings released: EPS: NT$0.97 (vs NT$1.17 in 1Q 2021)

Less than half of directors are independent

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$0.89 (vs NT$0.64 in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.73 in 2Q 2020)

Upcoming dividend of NT$1.80 per share

First quarter 2021 earnings released: EPS NT$1.17 (vs NT$0.67 in 1Q 2020)

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.

Full year 2020 earnings released: EPS NT$2.93 (vs NT$2.11 in FY 2019)

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 18, 2021

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?

Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?

Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?

New 90-day low: NT$35.20

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

New 90-day low: NT$36.50

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Third quarter 2020 earnings released: EPS NT$0.64

New 90-day low: NT$37.55

New 90-day low: NT$37.70

New 90-day low - NT$38.30

First half earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin